1. Home
  2. AREB vs GNPX Comparison

AREB vs GNPX Comparison

Compare AREB & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AREB

American Rebel Holdings Inc.

N/A

Current Price

$0.14

Market Cap

5.5M

Sector

Industrials

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$1.93

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AREB
GNPX
Founded
2014
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
AREB
GNPX
Price
$0.14
$1.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.5M
824.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.14
52 Week High
$28.00
$12.97

Technical Indicators

Market Signals
Indicator
AREB
GNPX
Relative Strength Index (RSI) 37.58 43.68
Support Level $0.12 $1.90
Resistance Level $1.34 $2.51
Average True Range (ATR) 0.02 0.20
MACD 0.01 0.01
Stochastic Oscillator 23.65 12.54

Price Performance

Historical Comparison
AREB
GNPX

About AREB American Rebel Holdings Inc.

American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Share on Social Networks: